Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
Start Date
9/24/2025
Completion Date
5/1/2029
Summary
This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)
Control
Conditions
Locations
University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
United States
Jacobs Medical Center
La Jolla, California 92037
United States
UF Health Jacksonville
Jacksonville, Florida 32209
United States
Advent Health
Orlando, Florida 32803
United States
Memorial Hospital of South Bend
South Bend, Indiana 46601
United States
Goryeb Children's Hospital
Morristown, New Jersey 07960
United States
The Trustees of Columbia University in the City of New York
New York, New York 10032
United States
Montefiore Medical Center
The Bronx, New York 10461
United States
Maria Farreri Children's Hospital
Valhalla, New York 10595
United States
Christus Children's Hospital
San Antonio, Texas 78207
United States
University of Virginia School of Medicine
Charlottesville, Virginia 22903
United States
WVU Medicine Children's Hospital
Morgantown, West Virginia 26506
United States